Literature DB >> 1936061

Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery.

M C Nahata1, D E Durrell, M E Ginn-Pease, D R King.   

Abstract

Limited information is available on the pharmacokinetics and tissue penetration of cefazolin in pediatric patients. Nine children (age 0.8-10 years) undergoing gastrointestinal operations were studied. A single dose of cefazolin, 15-26 mg/kg was given i.v. over 2-3 min at the time of induction of anaesthesia. Multiple (5-8) blood samples were collected during the operative procedure and in the recovery room. Tissue samples from the rectus abdominis muscle were obtained at the time of incision, during surgery, and at closure. The concentration of cefazolin was measured by a high performance liquid chromatographic method. Peak serum concentrations of cefazolin ranged from 85.8-269.4 mcg/ml. Serum and tissue concentrations at incision were 50.5-169.9 mcg/ml and 1.8-29.7 mcg/g; at closure the serum and tissue concentrations ranged from 17.3-60.9 mcg/ml and 1.19-29.70 mcg/g, respectively. Total clearance, apparent distribution volume, and elimination half-life of cefazolin were 1.43 +/- 0.54 ml/min/kg, 0.08 +/- 0.03 l/kg, and 1.68 +/- 0.55 h respectively. Tissue concentrations of cefazolin were maintained above its minimum inhibitory concentrations against common susceptible pathogens. Hence, the current dosing regimen of cefazolin is adequate to protect against infection in pediatric patients undergoing gastrointestinal surgery.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936061     DOI: 10.1007/BF03189874

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  3 in total

1.  Comparative penetration of cefonicid and cefazolin into the atrial appendage and pericardial fluid of patients undergoing open-heart surgery.

Authors:  M N Dudley; C H Nightingale; A D Drezner; H B Low; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

2.  Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts.

Authors:  Y Deguchi; R Koshida; E Nakashima; R Watanabe; N Taniguchi; F Ichimura; A Tsuji
Journal:  J Pharm Sci       Date:  1988-08       Impact factor: 3.534

3.  Antibiotic concentrations in pus and bone of children with osteomyelitis.

Authors:  T R Tetzlaff; J B Howard; G H McCraken; E Calderon; J Larrondo
Journal:  J Pediatr       Date:  1978-01       Impact factor: 4.406

  3 in total
  6 in total

1.  An additional dose of cefazolin for intraoperative prophylaxis.

Authors:  H Ohge; Y Takesue; T Yokoyama; Y Murakami; E Hiyama; Y Yokoyama; T Kanehiro; H Itaha; Y Matsuura
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years.

Authors:  Michael L Schmitz; Jeffrey L Blumer; Wes Cetnarowski; Christopher M Rubino
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

Review 3.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Are children undergoing cardiac surgery receiving antibiotics at subtherapeutic levels?

Authors:  Jennifer H Huang; Rachel Sunstrom; Myrna Y Munar; Ganesh Cherala; Arthur Legg; Ali J Olyeai; Stephen M Langley
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-15       Impact factor: 5.209

5.  Cefazolin pharmacokinetics in premature infants.

Authors:  Stephen J Balevic; P Brian Smith; Daniela Testoni; Huali Wu; Kim L R Brouwer; Kanecia O Zimmerman; Nazario D Rivera-Chaparro; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Perinatol       Date:  2019-04-03       Impact factor: 3.225

6.  Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients.

Authors:  Michael L Schmitz; Christopher M Rubino; Nikolas J Onufrak; Diana Valencia Martinez; Diane Licursi; Angela Karpf; Wes Cetnarowski
Journal:  J Clin Pharmacol       Date:  2020-12-09       Impact factor: 3.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.